ArriVent BioPharma, Inc. Statistics
Want to see AVBP full AI Analyst Report?
ArriVent BioPharma, Inc. (AVBP) Stock Statistics & Valuation Metrics
Total Valuation
ArriVent BioPharma, Inc. has a market cap or net worth of $697.74M. The enterprise value is $1.11B.
- Market Cap
- $697.74M
- Enterprise Value
- $1.11B
Share Statistics
ArriVent BioPharma, Inc. has 51,723,076 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 51,723,076
- Owned by Insiders
- 8.70%
- Owned by Institutions
- 24.26%
Financial Efficiency
ArriVent BioPharma, Inc.’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -57.78%.
- Return on Equity (ROE)
- -0.54
- Return on Assets (ROA)
- -0.50
- Return on Invested Capital (ROIC)
- -57.78%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.16M
- Employee Count
- 77
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ArriVent BioPharma, Inc. is -3.69. ArriVent BioPharma, Inc.’s PEG ratio is -0.36.
- PE Ratio
- -3.69
- PS Ratio
- 139.70
- PB Ratio
- 1.70
- Price to FCF
- -4.57
- Price to Operating Cash Flow
- -4.38
- PEG Ratio
- -0.36
Income Statement
In the last 12 months, ArriVent BioPharma, Inc. had revenue of 0 and earned -166.31M in profits. Earnings per share was -4.32.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -177.53M
- Pretax Income
- -166.31M
- Net Income
- -166.31M
- EBITDA
- -166.31M
- Earnings Per Share (EPS)
- -4.32
Cash Flow
In the last 12 months, operating cash flow was -152.84M and capital expenditures 0, giving a free cash flow of -152.84M billion.
- Operating Cash Flow
- -152.84M
- Free Cash Flow
- -152.84M
- Free Cash Flow per Share
- -3.09
Dividends & Yields
ArriVent BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.44%
- Earnings Yield
- -25.93%
Stock Price Statistics
- Beta
- 1.25
- 52-Week Price Change
- -30.31%
- 50-Day Moving Average
- 22.41
- 200-Day Moving Average
- 26.73
- Relative Strength Index (RSI)
- 35.49
- Average Volume (3m)
- 1.30M
Important Dates
ArriVent BioPharma, Inc. upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
ArriVent BioPharma, Inc. as a current ratio of 12.83, with Debt / Equity ratio of 0.00%
- Current Ratio
- 12.83
- Quick Ratio
- 12.83
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.27
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, ArriVent BioPharma, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
ArriVent BioPharma, Inc. EV to EBITDA ratio is -3.30, with an EV/FCF ratio of -3.71.
- EV to Sales
- 113.54
- EV to EBITDA
- -3.30
- EV to Free Cash Flow
- -3.71
- EV to Operating Cash Flow
- -3.71
Balance Sheet
ArriVent BioPharma, Inc. has $393.22M in cash and marketable securities with $256.00K in debt, giving a net cash position of $392.97M billion.
- Cash & Marketable Securities
- $393.22M
- Total Debt
- $256.00K
- Net Cash
- $392.97M
- Net Cash Per Share
- $7.60
- Tangible Book Value Per Share
- $7.94
Margins
Gross margin is 100.00%, with operating margin of -3620.02%, and net profit margin of -3381.40%.
- Gross Margin
- 100.00%
- Operating Margin
- -3620.02%
- Pretax Margin
- -3381.40%
- Net Profit Margin
- -3381.40%
- EBITDA Margin
- -3442.66%
- EBIT Margin
- -3442.66%
Analyst Forecast
The average price target for ArriVent BioPharma, Inc. is $24.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $24.20
- Price Target Upside
- 79.19% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 13.57%
Scores
- Smart Score
- 7
- AI Score
- 47
